Total Synthesis of the Antimycobacterial Natural Product Chlorflavonin and Analogs via a Late-Stage Ruthenium(II)-Catalyzed ortho-C(sp2)-H-Hydroxylation
Journal Article
2022-08-10
Permanent link to this Item
Authors
Journal Title
Pharmaceuticals
Link to Journal
Journal ISSN
Volume Title
Publisher
Publisher
Department
Faculty
Series
Abstract
The continuous, worldwide spread of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) endanger the World Health Organization’s (WHO) goal to end the global TB pandemic by the year 2035. During the past 50 years, very few new drugs have been approved by medical agencies to treat drug-resistant TB. Therefore, the development of novel antimycobacterial drug candidates to combat the threat of drug-resistant TB is urgent. In this work, we developed and optimized a total synthesis of the antimycobacterial natural flavonoid chlorflavonin by selective ruthenium(II)-catalyzed <i>ortho</i>-C(sp<sup>2</sup>)-H-hydroxylation of a substituted 3′-methoxyflavonoid skeleton. We extended our methodology to synthesize a small compound library of 14 structural analogs. The new analogs were tested for their antimycobacterial in vitro activity against <i>Mycobacterium tuberculosis</i> (<i>Mtb</i>) and their cytotoxicity against various human cell lines. The most promising new analog bromflavonin exhibited improved antimycobacterial in vitro activity against the virulent H37Rv strain of <i>Mtb</i> (Minimal Inhibitory Concentrations (MIC<sub>90</sub>) = 0.78 μm). In addition, we determined the chemical and metabolic stability as well as the p<i>K</i><sub>a</sub> values of chlorflavonin and bromflavonin. Furthermore, we established a quantitative structure–activity relationship model using a thermodynamic integration approach. Our computations may be used for suggesting further structural changes to develop improved derivatives.
Description
Reference:
Pharmaceuticals 15 (8): 984 (2022)
Pharmaceuticals 15 (8): 984 (2022)